Veerhealth Care Limited
P&L
Quarterly Standalone
Veerhealth Care Reports 388% YoY Revenue Growth in Q1FY27
17 Aug 2026 · 1d ago, 8:56 am
Summary
Veerhealth Care Limited has reported its Q1FY27 standalone results, showcasing exceptional YoY growth across key financial metrics. Total Revenues surged by 388.13% to ₹ 25.09 Crore, while EBITDA grew by 233.87% to ₹ 2.07 Crore. Net Profit saw a remarkable increase of 412.50% to ₹ 1.23 Crore. The company also announced several high-value orders and highlighted strategic achievements such as USFDA clearance for exports and progress in entering the Russian market. Management expressed delight with the record quarterly performance, driven by international expansion and new product categories, and anticipates maintaining high growth rates.
Key Highlights
- 1
Veerhealth Care Limited reported Q1FY27 Total Revenues of ₹ 25.09 Crore, achieving a significant YoY growth of 388.13%.
- 2
EBITDA for Q1FY27 stood at ₹ 2.07 Crore, marking a substantial YoY increase of 233.87%.
- 3
The company achieved a Net Profit of ₹ 1.23 Crore in Q1FY27, representing an impressive YoY growth of 412.50%.
- 4
Veerhealth Care secured multiple significant orders in FY27, including orders from a New York-based company for ₹293 Lakhs and an Indian FMCG company for ₹1824.40 Lakhs.
- 5
The company received USFDA clearance, enabling exports of Drug (OTC) products to the USA and other international markets.
- 6
Discussions with a major Russian group for oral care exports have entered an advanced stage, with expected entry into the Russian market soon.
- 7
Veerhealth Care commenced production at a new facility with in-house plastic molding for packaging and backward integration.
Management Comments
Bhavin Shah
I am delighted with the progress we have made in QIFY27 by reporting Highest ever Quarterly Total Income of 725.09 crore, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets. Going ahead we expect to maintain the high growth rates which we have delivered till now in this Financial Year. Our ability to secure multiple high-value export orders, including those from top institutional suppliers, underscores the trust in our product quality and commitment to excellence. The expansion of our manufacturing footprint further reflects our proactive approach to meeting growing demand and enhancing our production capabilities. These achievements are a testament {o our strategy and pave the way for sustained growth and value creation in the coming quarters.
Informational and educational content only. Not investment advice.